Sun Pharmaceutical shares have tumbled nearly 8% in August, underperforming the broader Sensex and nearing year-low levels. The slump is linked to US pressure on pricing policies and tariff concerns.
Will Sun Pharma’s dip bring broader investor scrutiny on India’s pharma giants?
Could this spark a shift toward more conservative pipelines over aggressive expansion?
Is this a blip or a signal that Indian pharma needs hedging not just volume but higher-margin innovation?
MBH/AB